MedTrace Logo

Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza

NCT06817096 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2025-02-10

No results posted yet for this study

Summary

2\. Participants will:

* Take nitazoxanide 600mg (or placebo) orally twice daily for 7 days, for a total of 14 doses.
* Visit the clinic on the 7th day of treatment for a check-up and safety tests.
* Keep a diary of their symptoms and other medications used

Conditions

Interventions

DRUG

Nitazoxanide 600Mg Oral Tablet / placebo oral tablet

1 tablet every 12 hours

Sponsors & Collaborators

  • Farmoquimica S.A.

    collaborator INDUSTRY

  • Azidus Brasil

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-28
Primary Completion
2026-12-31
Completion
2027-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06817096 on ClinicalTrials.gov